此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old (MYAMERGE)

2026年11月10日 更新者:Biogen

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis

In this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells.

In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase).

In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again.

The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine.

The main question researchers want to answer is:

  • Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies?

Researchers will also learn more about:

  • How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.
  • How the body processes felzartamab
  • How felzartamab affects the participants' disease severity
  • How many participants' bodies make antibodies against felzartamab after treatment

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.

  • Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have.

    • If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo.
    • If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking.
  • Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein.

  • During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives.

  • After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

The primary objective of this study is to evaluate the efficacy of felzartamab in participants with gMG compared with placebo. The secondary objectives of this study are to evaluate the efficacy, safety, pharmacokinetics (PK) of felzartamab and anti-drug antibodies (ADAs) in participants with gMG.

研究类型

介入性

注册 (估计的)

75

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Documented diagnosis of gMG.
  • Myasthenia Gravis Foundation of America (MGFA) clinical Classification II to IVa at Screening and Randomization.
  • Corticosteroids must be administered orally on a daily or alternate-day schedule; pulse corticosteroid therapy is not permitted. Concomitant treatment with permitted acetylcholinesterase inhibitor (AChEIs) and/or allowed conventional immunosuppressant standard therapy (ISTs) is allowed, provided all therapies meet protocol-defined requirements.
  • Participants receiving AChEIs must have been on a stable dose prior to Randomization.
  • Participants receiving Azathioprine must be on treatment and a stable dose prior to Randomization.
  • Participants receiving other conventional immunosuppressive drugs (e.g., mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, tacrolimus), or other Sponsor-approved therapy) must be on treatment and on a stable dose prior to Randomization.
  • Participants should be up to date on all vaccinations in accordance with local country or regional public health authority guidelines, where feasible. Required vaccinations should be completed at least 4 weeks prior to screening, where applicable. A screening period extension may be permitted to allow completion of required vaccinations.

Key Exclusion Criteria:

  • MGFA Class I or IVb, or V at Screening.
  • History of myasthenic crisis requiring hospitalization, mechanical ventilation, or intensive care unit admission prior to Screening.
  • Anticipated need for rescue therapy between Screening and Randomization.
  • Congenital myasthenic syndrome, Lambert-Eaton myasthenic syndrome, or any other neuromuscular disorder that could confound the evaluation of gMG.
  • Thymectomy for benign thymoma within 12 months prior to Randomization or planned thymectomy during the study.
  • Unresected, active or recurrent thymoma.
  • History of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer, or other malignancies considered cured with minimal risk of recurrence, as determined by the Investigator.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: Felzartamab or Placebo

Participants will receive multiple intravenous (IV) doses of felzartamab or placebo.

Administered IV

Administered IV

其他名称:
  • MOR202
  • 莫尔03087
  • TJ202
  • BIIB148
实验性的:Cohort 2: Felzartamab

Participants will receive multiple IV doses of felzartamab.

Administered IV

其他名称:
  • MOR202
  • 莫尔03087
  • TJ202
  • BIIB148

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Cohort 1: Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
大体时间:Baseline, Week 26
Baseline, Week 26

次要结果测量

结果测量
大体时间
Cohort 1: Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
大体时间:Baseline, Week 26
Baseline, Week 26
Cohorts 1 and 2: Number of Participants With Adverse Events (AEs) and Adverse Events of Special Interest (AESI)
大体时间:From first dose of study drug up to end of study follow-up (Up to Week 52)
From first dose of study drug up to end of study follow-up (Up to Week 52)
Cohorts 1 and 2: Felzartamab Serum Concentrations Over Time
大体时间:Predose and at multiple timepoints postdose up to Week 44
Predose and at multiple timepoints postdose up to Week 44
Cohorts 1and 2: Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
大体时间:Baseline up to Week 52
Baseline up to Week 52

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Medical Director、Biogen

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月19日

初级完成 (估计的)

2028年9月19日

研究完成 (估计的)

2029年3月20日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 299MG201
  • 2026-527803-94 (其他标识符:EU CT Number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.